Literature DB >> 3778259

Simultaneous recording of pattern electroretinography and visual evoked potentials in multiple sclerosis. A method to separate demyelination from axonal damage to the optic nerve.

G G Celesia, D Kaufman, S B Cone.   

Abstract

Pattern electroretinograms (P-ERGs) and visual evoked potentials (VEPs) were recorded in 35 patients with multiple sclerosis and in 35 age-matched normal subjects. Four patterns of abnormalities were noted in the group with multiple sclerosis. The most frequent abnormality consisted of the following: normal P-ERG, delayed P100, and prolonged interpeak interval between the b-wave of the P-ERG and P100 (retinocortical time). This pattern indicates demyelination of the optic nerve. A second pattern consisted of absent P-ERG and absent VEP. This pattern was associated with optic atrophy and/or central scotoma, indicating severe optic nerve axonopathy with retrograde degeneration of ganglion cells. A third pattern consisted of normal P-ERG and absent VEP, suggesting a total block of transmission at the optic nerve. A fourth pattern consisted of present but low-amplitude P-ERG, delayed VEP, and prolonged retinocortical time, indicating a demyelinating process with partial axonal involvement. The concomitant use of P-ERG and VEP results in a better classification of the type and severity of dysfunction affecting the optic nerve. The prognostic value of the four patterns for recovery of visual function is discussed.

Entities:  

Mesh:

Year:  1986        PMID: 3778259     DOI: 10.1001/archneur.1986.00520120031012

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  12 in total

1.  Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5'-diphosphocholine (citicoline): a study of 8 years of follow-up.

Authors:  Vincenzo Parisi
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

2.  Pattern electroretinogram as a function of spatial frequency after retrobulbar optic neuritis.

Authors:  B Falsini; A Bardocci; S Cermola; V Porciatti; G Porrello
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

3.  Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease.

Authors:  Ozgül Altintaş; Pervin Işeri; Berna Ozkan; Yusuf Cağlar
Journal:  Doc Ophthalmol       Date:  2007-10-26       Impact factor: 2.379

4.  Pattern electroretinogram in neuromyelitis optica and multiple sclerosis with or without optic neuritis and its correlation with FD-OCT and perimetry.

Authors:  Kenzo Hokazono; Ali S Raza; Maria K Oyamada; Donald C Hood; Mário L R Monteiro
Journal:  Doc Ophthalmol       Date:  2013-07-30       Impact factor: 2.379

5.  Neural conduction in the visual pathways in ocular hypertension and glaucoma.

Authors:  V Parisi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-03       Impact factor: 3.117

6.  VEP and PERG in patients with multiple sclerosis, with and without a history of optic neuritis.

Authors:  M Janáky; Á Jánossy; G Horváth; G Benedek; G Braunitzer
Journal:  Doc Ophthalmol       Date:  2017-04-18       Impact factor: 2.379

7.  Clinical application of motion-onset visual evoked potentials.

Authors:  Z Kubová; M Kuba
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

8.  Pattern electroretinogram peak times as a clinical means of discriminating retinal from optic nerve disease.

Authors:  R Lorenz; E Dodt; W Heider
Journal:  Doc Ophthalmol       Date:  1989-03       Impact factor: 2.379

Review 9.  Visual Pathway Degeneration in Chemotherapy-Related Neurotoxicity: A Review and Directions for Future Research.

Authors:  David E Anderson; Sarah A Holstein; Sachin Kedar
Journal:  Neuroophthalmology       Date:  2020-01-06

10.  Retinocortical conduction time in diabetics with abnormal pattern reversal electroretinograms and visual evoked potentials.

Authors:  G L Trick; R M Burde; M O Gordon; C Kilo; J V Santiago
Journal:  Doc Ophthalmol       Date:  1988-09       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.